Phase 1 randomized open-label blinded endpoint trial

Oral administration 60 mg of BMS-986120 (n=20)

- Reversible and selective inhibition of PAR4 AP stimulated platelet activation and aggregation
- ↓ *ex vivo* thrombus formation at high shear stress (1690 s^{-1})
- Reductions in thrombosis driven by ↓ platelet-rich thrombus formation
- No effect on coagulation times or serious adverse events